Pembrolizumab/Radiation/Surgery Improves DFS in Stage III Soft Tissue Sarcoma
The addition of pembrolizumab to preoperative radiation therapy followed by surgery prolonged DFS in patients with soft tissue sarcoma of the extremity.
Related Articles
Avapritinib Yields Improvements in Bone Density in Advanced Systemic Mastocytosis
Treatment with avapritinib was associated with dynamic changes in bone density based on lumbar T-scores among patients with systemic mastocytosis.
FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer
The ACR-368 OncoSignature assay has received breakthrough device designation from the FDA for use in endometrial cancer.
Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence
Arce-Gallego et al. integrate next-generation sequencing with a RAD51 immunofluorescence assay to assess HRR function in advanced prostate cancer. They link RAD51-IF scores to mutations in…
Early Diagnosis and Treatment Are Critical in Achieving the Best Outcomes in Sarcoma
Breelyn Wilky, MD, discusses the importance of disease screening and early diagnosis in the treatment of patients with sarcoma.
Artificial Intelligence in Cancer Care and Clinical Trials
Arturo Loaiza-Bonilla, MD, discusses artificial intelligence in cancer care and clinical trials.
Cancer Statistics for 2025 – Oncology Nurse Advisor
More than 2 million new cases of cancer will be diagnosed in the US this year, and more than 600,000 people will die of cancer,…
Early Palliative Care Improves EOL Comfort in Colorectal Cancer
Early palliative care reduces invasive interventions and enhances comfort at EOL for CRC patients, according to real-world study results.
OncLive’s FDA Approval Report: The Regulatory Rundown for January 2025
Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.
Direct Oral Anticoagulants in Extended Treatment of Venous… : Oncology Times
An abstract is unavailable.
‘Call to action’: Head and neck cancer trials in US becoming less diverse
Despite focused efforts to improve the diversity of clinical trials, representation in research into head and neck cancer has become less equitable over the past…
